For one type of psychedelic, dosing poses challenges. Scientists at Lusaris Therapeutics believe their approach can win out and the biotech startup has raised $60 million to bring its lead drug ...

Lusaris Therapeutics this month spun out of Boston ... Lusaris expects to have data from this study by mid-2023. The company's pipeline includes two other preclinical programs, one of which ...

Biotech company focused on creating next-gen serotonergic neuroplastogen psychedelic compounds to treat severe neuropsychiatric and neurological conditions Lusaris Therapeutics launched with a $ ...

Please provide your email address to receive an email when new articles are posted on . Lusaris Therapeutics announced its launch with $60 million in Series A financing to advance LSR-1019, a ...

Lusaris Therapeutics announced plans to set up shop ... and fast-acting serotonergic psychedelic compound. The company’s pipeline also includes two additional early stage drug candidates for ...

Lusaris Therapeutics has announced plans to set ... and fast-acting serotonergic psychedelic compound. The company’s pipeline also includes two additional early stage drug candidates for ...

“Coming out of COVID, there was a mental health focus coming into play,” said Andrew Levin, partner and managing director at investment firm RA Capital Management who is also serving as interim CEO at ...

there would be no mRNA vaccines for COVID-19 Lusaris Therapeutics has launched with $60 million in series A financing to develop therapies for severe neuropsychiatric and neurological conditions.